Logo image of CEMI

CHEMBIO DIAGNOSTICS INC (CEMI) Stock Fundamental Analysis

NASDAQ:CEMI - Nasdaq - US1635722093 - Common Stock - Currency: USD

0.455  +0 (+0.22%)

After market: 0.4311 -0.02 (-5.25%)

Fundamental Rating

1

Overall CEMI gets a fundamental rating of 1 out of 10. We evaluated CEMI against 190 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of CEMI have multiple concerns. CEMI does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CEMI has reported negative net income.
CEMI had a negative operating cash flow in the past year.
In the past 5 years CEMI always reported negative net income.
In the past 5 years CEMI always reported negative operating cash flow.
CEMI Yearly Net Income VS EBIT VS OCF VS FCFCEMI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 -10M -20M -30M

1.2 Ratios

CEMI has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CEMI Yearly ROA, ROE, ROICCEMI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 -20 -40 -60 -80 -100

1.3 Margins

CEMI's Gross Margin of 22.10% is on the low side compared to the rest of the industry. CEMI is outperformed by 78.20% of its industry peers.
In the last couple of years the Gross Margin of CEMI has declined.
CEMI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 22.1%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.23%
GM growth 5Y-13.7%
CEMI Yearly Profit, Operating, Gross MarginsCEMI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 20 -20 40 -40 -60

More info and screens

2

2. Health

2.1 Basic Checks

CEMI does not have a ROIC to compare to the WACC, probably because it is not profitable.
CEMI has more shares outstanding than it did 1 year ago.
CEMI has a worse debt/assets ratio than last year.
CEMI Yearly Shares OutstandingCEMI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M
CEMI Yearly Total Debt VS Total AssetsCEMI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -3.34, we must say that CEMI is in the distress zone and has some risk of bankruptcy.
CEMI has a worse Altman-Z score (-3.34) than 65.40% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that CEMI is not too dependend on debt financing.
With a decent Debt to Equity ratio value of 0.00, CEMI is doing good in the industry, outperforming 65.88% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.34
ROIC/WACCN/A
WACC9.13%
CEMI Yearly LT Debt VS Equity VS FCFCEMI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 20M -20M

2.3 Liquidity

CEMI has a Current Ratio of 1.23. This is a normal value and indicates that CEMI is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.23, CEMI is doing worse than 82.94% of the companies in the same industry.
A Quick Ratio of 1.04 indicates that CEMI should not have too much problems paying its short term obligations.
The Quick ratio of CEMI (1.04) is worse than 78.67% of its industry peers.
Industry RankSector Rank
Current Ratio 1.23
Quick Ratio 1.04
CEMI Yearly Current Assets VS Current LiabilitesCEMI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M

More info and screens

2

3. Growth

3.1 Past

CEMI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 45.07%, which is quite impressive.
CEMI shows a small growth in Revenue. In the last year, the Revenue has grown by 3.57%.
CEMI shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 15.57% yearly.
EPS 1Y (TTM)45.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.95%
Revenue 1Y (TTM)3.57%
Revenue growth 3Y12.85%
Revenue growth 5Y15.57%
Sales Q2Q%-49.72%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CEMI Yearly Revenue VS EstimatesCEMI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M
CEMI Yearly EPS VS EstimatesCEMI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CEMI. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CEMI Price Earnings VS Forward Price EarningsCEMI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CEMI Per share dataCEMI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

CEMI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CHEMBIO DIAGNOSTICS INC

NASDAQ:CEMI (4/27/2023, 8:20:06 PM)

After market: 0.4311 -0.02 (-5.25%)

0.455

+0 (+0.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-09 2023-03-09
Earnings (Next)05-09 2023-05-09
Inst Owners0%
Inst Owner Change0%
Ins Owners7.8%
Ins Owner Change0%
Market Cap16.71M
Analysts43.33
Price Target8.16 (1693.41%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.34
P/FCF N/A
P/OCF N/A
P/B 0.94
P/tB 0.94
EV/EBITDA N/A
EPS(TTM)-0.75
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.39
FCFYN/A
OCF(TTM)-0.35
OCFYN/A
SpS1.35
BVpS0.48
TBVpS0.48
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 22.1%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.23%
GM growth 5Y-13.7%
F-Score3
Asset Turnover0.79
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 56.84%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.23
Quick Ratio 1.04
Altman-Z -3.34
F-Score3
WACC9.13%
ROIC/WACCN/A
Cap/Depr(3y)91.56%
Cap/Depr(5y)127.18%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)45.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.95%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)3.57%
Revenue growth 3Y12.85%
Revenue growth 5Y15.57%
Sales Q2Q%-49.72%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y15.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y56.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y58.9%
OCF growth 3YN/A
OCF growth 5YN/A